HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HX-009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HX-009 overview
HX-009 is under development for the treatment of advanced solid tumors including metastatic biliary tract cancer, head and neck cancers, esophageal cancers, sarcoma, malignant mesothelioma, relapsed/refractory diffuse large B-cell lymphoma, peripheral T-cell lymphoma, NK/T-cell lymphoma, classic Hodgkin's lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, melanoma and relapsed/refractory lymphoma. The therapeutic candidate is a bi-specific antibody fusion protein which is administered by intravenous route. It acts by targeting programmed cell death protein-1 and CD47.
For a complete picture of HX-009’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
